New research being presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that women are much more aware of and knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide).
This article was originally published on MedicalXpress.com
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
© 2025 SimplyWell.ca